101 signals · alpha_vantage, bluesky, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Elevated risk signals — operational or reputational pressure patterns observed.
Auto-generated from public signals — AI summary pending. Based on 3 recent signals.
Regeneron Pharmaceuticals (REGN) Could Be 11% Overvalued Following Its Earnings Beat Simply Wall St
B of A Securities maintains Regeneron Pharmaceuticals at Buy, raises price target to $1030 from $908 TradingView
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $913.00 MarketBeat
Biotechnology company with a focus on genetics.
Based on 101 signals across 3 sources · snapshot 4 Nov 2026
Strong: enough recent evidence to trust this score.
Overall community sentiment for Regeneron is mixed based on public signals as of 4 Nov 2026.
Based on 101 signals across 3 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.